dihexa fda approval status clinical trials Dihexa shows neurotrophic activity exceeding BDNF in preclinical studies DIHEXA PEPTIDE 10MG VIAL –

*This product is administered via injection, and it requires bacteriostatic water for reconstitution

Avoid tight clothing or harsh rubbing on the injection site

Experimental evidence from knockout models suggests that reduced NNMT activity is associated with resistance to tumor formation, leading to speculation about a possible role for this enzyme in cancer biology

Product Care Store unopened vials at 20C25C (68F77F) Protect from excessive heat and direct light Maintain sterile handling during research use Intended Use This product is intended exclusively for qualified laboratory researchers

In very rare cases, the recipient may develop blood clots, mild skin rashes, and anaphylactic reactions

Combining these two unpredictable factors creates a chaotic metabolic environment